Novartis AG (BCBA:NVS)
Argentina · Delayed Price · Currency is ARS | Market Cap | 389.95T +86.7% |
| Revenue (ttm) | 78.16T +6.3% |
| Net Income | 18.70T +5.2% |
| EPS | 9,644.32 +9.5% |
| Shares Out | n/a |
| PE Ratio | 20.86 |
| Forward PE | 16.36 |
| Dividend | 988.41 (1.78%) |
| Ex-Dividend Date | Mar 11, 2026 |
| Volume | 248 |
| Average Volume | 213 |
| Open | 54,425 |
| Previous Close | 53,400 |
| Day's Range | 54,350 - 55,500 |
| 52-Week Range | 30,425 - 63,200 |
| Beta | n/a |
| RSI | 49.97 |
| Earnings Date | Apr 28, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsNews
November 20th Options Now Available For Novartis (NVS)
Investors in Novartis (Symbol: NVS) saw new options become available today, for the November 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the t...
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina
Novartis (NVS) Expands Manufacturing with New Facility in North Carolina
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
The IgAN market is growing due to rising prevalence, improved diagnostics, novel immunotherapies, ongoing clinical trials of therapies such as Zigakibart (Novartis), Sefaxersen (F. Hoffmann-La Roche/I...
Noteworthy ETF Inflows: AVDE, SHEL, HSBC, NVS
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Avantis International Equity ETF (Symbol: AVDE) where we have detected...
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant...
Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income ...
Novartis AG (NVS) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amidst Core Income Challenges
Q1 2026 Novartis AG Earnings Call Transcript
Q1 2026 Novartis AG Earnings Call Transcript
Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal
Novartis Expands R&D Spending Up To $70 Million Monthly After Avidity Deal
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO on Q1 earnings miss
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss the company's latest earnings report, policies around drug pricing, and more.
Watch CNBC's full interview with Novartis CEO Vas Narasimhan
Novartis CEO Vas Narasimhan joins 'Money Movers' to discuss the company's latest earnings report, policies around drug pricing, and more.
Novartis Stock Declines After Q1 Revenue Misses Expectations
Novartis Stock Declines After Q1 Revenue Misses Expectations
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales
Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.
Novartis AG Earnings Call Transcript: Q1 2026
Priority brands and new launches drove strong Q1 growth, offsetting U.S. generic erosion and higher R&D spend. Full-year guidance is reaffirmed, with H2 expected to show stronger growth as generic impacts fade. Multiple pipeline readouts and new launches are set to support long-term growth.
Novartis (NVS) Reports Q1 Sales and Pipeline Progress
Novartis (NVS) Reports Q1 Sales and Pipeline Progress
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generic Competition
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generic Competition
Novartis CEO Warns of Drug Pricing Policy Impact on Pharma Sector
Novartis CEO Warns of Drug Pricing Policy Impact on Pharma Sector
The reality of MFN drug pricing is going to set in over 'next 18 months,' says Novartis CEO
President Donald Trump's drug pricing policy will have a "significant" impact on drugmakers and patients over the longer term, says Novartis CEO Vas Narasimhan.
Novartis Faces Challenges Ahead of Q1 2026 Earnings
Novartis Faces Challenges Ahead of Q1 2026 Earnings
Novartis Earnings Hit by Generic Competition
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugma...
Novartis misses in Q1 but sticks with full-year outlook
Novartis misses in Q1 but sticks with full-year outlook